RepliCel Accounts Payable vs Cash And Short Term Investments Analysis
RP Stock | CAD 0.01 0.00 0.00% |
RepliCel Life financial indicator trend analysis is much more than just breaking down RepliCel Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RepliCel Life Sciences is a good investment. Please check the relationship between RepliCel Life Accounts Payable and its Cash And Short Term Investments accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Accounts Payable vs Cash And Short Term Investments
Accounts Payable vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RepliCel Life Sciences Accounts Payable account and Cash And Short Term Investments. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between RepliCel Life's Accounts Payable and Cash And Short Term Investments is -0.27. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of RepliCel Life Sciences, assuming nothing else is changed. The correlation between historical values of RepliCel Life's Accounts Payable and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of RepliCel Life Sciences are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Accounts Payable i.e., RepliCel Life's Accounts Payable and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | -0.27 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents RepliCel Life obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of RepliCel Life Sciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of RepliCel Life Sciences balance sheet. This account contains RepliCel Life investments that will expire within one year. These investments include stocks and bonds that can be liquidated by RepliCel Life Sciences fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Most indicators from RepliCel Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RepliCel Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, RepliCel Life's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 5.46 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.54) in 2024.
RepliCel Life fundamental ratios Correlations
Click cells to compare fundamentals
RepliCel Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
RepliCel Life fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 505.5K | 421.0K | 591.8K | 798.2K | 287.8K | 273.4K | |
Total Current Liabilities | 1.6M | 2.2M | 1.7M | 2.1M | 1.8M | 1.9M | |
Total Stockholder Equity | (4.4M) | (5.1M) | (6.8M) | (5.9M) | (4.5M) | (4.3M) | |
Property Plant And Equipment Net | 6.0K | 4.4K | 3.3K | 2.4K | 967.0 | 918.65 | |
Net Debt | 425.4K | 41.7K | (186.9K) | (372.1K) | 754.0K | 791.7K | |
Retained Earnings | (36.6M) | (38.2M) | (42.2M) | (43.0M) | (43.3M) | (41.1M) | |
Accounts Payable | 640.3K | 1.3M | 602.0K | 817.9K | 416.0K | 472.3K | |
Cash | 23.9K | 34.4K | 221.2K | 413.0K | 59.2K | 56.2K | |
Non Current Assets Total | 272.2K | 235.3K | 198.8K | 162.5K | 125.7K | 119.4K | |
Cash And Short Term Investments | 52.7K | 51.6K | 238.4K | 430.3K | 76.4K | 72.6K | |
Net Receivables | 51.9K | 63.6K | 61.2K | 82.2K | 38.0K | 39.0K | |
Common Stock Shares Outstanding | 24.1M | 27.0M | 32.5M | 37.8M | 59.2M | 62.2M | |
Liabilities And Stockholders Equity | 505.5K | 421.0K | 591.8K | 798.2K | 287.8K | 273.4K | |
Other Stockholder Equity | 4.6M | 4.6M | 5.1M | 5.4M | 5.6M | 5.6M | |
Total Liab | 4.9M | 5.5M | 7.4M | 6.7M | 4.8M | 5.1M | |
Total Current Assets | 233.2K | 185.7K | 393.0K | 635.7K | 162.1K | 154.0K | |
Short Term Debt | 449.3K | 47.3K | 611.4K | 689.3K | 813.2K | 853.8K | |
Common Stock | 27.5M | 28.5M | 30.3M | 31.7M | 33.1M | 20.0M | |
Other Current Liab | 107.3K | 517.8K | 106.6K | 211.8K | 239.5K | 432.0K | |
Other Assets | 266.2K | 230.8K | 195.5K | 1.0 | 1.15 | 1.09 | |
Non Current Liabilities Total | 3.4M | 3.2M | 5.8M | 4.6M | 3.0M | 2.1M | |
Other Current Assets | 128.7K | 70.5K | 93.4K | 123.2K | 47.7K | 89.2K | |
Net Tangible Assets | (1.9M) | (4.4M) | (5.1M) | (6.8M) | (6.2M) | (5.9M) | |
Property Plant Equipment | 8.2K | 6.0K | 4.4K | 3.3K | 2.9K | 2.8K | |
Net Invested Capital | (2.9M) | (5.0M) | (6.8M) | (5.9M) | (5.3M) | (5.6M) | |
Net Working Capital | (1.2M) | (2.1M) | (1.3M) | (1.4M) | (1.3M) | (1.4M) | |
Capital Stock | 29.0M | 28.5M | 30.3M | 31.7M | 36.4M | 32.6M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.